BRCA1/2 Mutations and Efficacy of Pembrolizumab-Based Neoadjuvant Chemotherapy in Triple-Negative Breast Cancer: A Real-World Multicenter Analysis
Palma Fedele(Ospedale A. Perrino), Gennaro Gadaleta‐Caldarola(University of Parma), Alessandro Rizzo(Istituto Tumori Bari), Antonella Terenzio(University of Foggia), Maria Morritti(Casa Sollievo della Sofferenza), Laura Lanotte, Matteo Landriscina(University of Foggia), Antonella Licchetta(Ospedale SS. Annunziata), Marianna Giampaglia(Ospedale San Carlo), Lucia Moraca(Hospital Madre Teresa), Raffaele Ardito(Centro di Riferimento Oncologico della Basilicata), Luigia Stefania Stucci, Francesco Giuliani(Ospedale San Paolo), Domenico Bilancia(Azienda Ospedaliera Ospedale San Carlo Borromeo), Antonio Gnoni(Ospedale Sacro Cuore Don Calabria), Giuseppe Cairo(Ospedale Vito Fazzi), Federica Fumai(Istituto di Istruzione Secondaria Superiore "V. Lilla" Francavilla Fontana - Oria), Assunta Melaccio(Ospedale San Paolo)
Cited by 1
Related Papers
Gemcitabine Plus Vinorelbine Versus Vinorelbine Alone in Elderly Patients With Advanced Non–Small-Cell Lung Cancer
|Journal of Clinical Oncology|2000|452
Randomized Trial Comparing Cisplatin, Gemcitabine, and Vinorelbine With Either Cisplatin and Gemcitabine or Cisplatin and Vinorelbine in Advanced Non–Small-Cell Lung Cancer: Interim Analysis of a Phase III Trial of the Southern Italy Cooperative Oncology Group
|Journal of Clinical Oncology|2000|177
Lapatinib in breast cancer
|Annals of Oncology|2007|129
Is There a Role for Immunotherapy in Prostate Cancer?
|Cells|2020|85